| Liv Health | |
|
2500 Dell Range Blvd Cheyenne WY 82009-5273 | |
| (307) 630-4729 | |
| Not Available |
| Full Name | Liv Health |
|---|---|
| Speciality | Clinic/Center |
| Location | 2500 Dell Range Blvd, Cheyenne, Wyoming |
| Authorized Official Name and Position | Emily Ann Loos (OWNER) |
| Authorized Official Contact | 3076304729 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Liv Health Po Box 20092 Cheyenne WY 82003-7002 Ph: (307) 630-4729 | Liv Health 2500 Dell Range Blvd Cheyenne WY 82009-5273 Ph: (307) 630-4729 |
| NPI Number | 1740604057 |
|---|---|
| Provider Enumeration Date | 02/06/2014 |
| Last Update Date | 10/05/2022 |
| Certification Date | 10/05/2022 |
| Medicare PECOS PAC ID | 5698992352 |
|---|---|
| Medicare Enrollment ID | O20140804002438 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740604057 | NPI | - | NPPES |
| 149078 | Medicaid | WY |
| Provider Name | Christine W Gray |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1033190152 PECOS PAC ID: 6709809593 Enrollment ID: I20060106000717 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Kristina L Stefka |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740339159 PECOS PAC ID: 7012903453 Enrollment ID: I20070516000475 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Emily Ann Loos |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1043553498 PECOS PAC ID: 5395986392 Enrollment ID: I20130801000783 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Patricia Engler-parish |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1265832737 PECOS PAC ID: 2264755149 Enrollment ID: I20141229001906 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Gregory V Stelzner |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1003179649 PECOS PAC ID: 5092022608 Enrollment ID: I20150915001365 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Lisa Otto |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1851707574 PECOS PAC ID: 7214299841 Enrollment ID: I20180320001165 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Jennifer Lindstrom |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770996357 PECOS PAC ID: 2365797735 Enrollment ID: I20180626003105 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Heather Madrid |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1912354101 PECOS PAC ID: 2062761133 Enrollment ID: I20180822002852 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Tessa Matzen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447792593 PECOS PAC ID: 8527318856 Enrollment ID: I20180907001847 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Ashlie Kay Irish |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922593037 PECOS PAC ID: 0648521849 Enrollment ID: I20180927001907 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Rachel E Eby |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1548644347 PECOS PAC ID: 3173873155 Enrollment ID: I20190123001802 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Julie Hummer-bellmyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265623870 PECOS PAC ID: 8527300870 Enrollment ID: I20190507001022 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Hanna R Powers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619500097 PECOS PAC ID: 7810325594 Enrollment ID: I20200311000679 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Natasha Trujillo |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1992107437 PECOS PAC ID: 9638593106 Enrollment ID: I20200717000581 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Marianne Denton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952936932 PECOS PAC ID: 0345667036 Enrollment ID: I20200826001463 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Robin Barry |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1598362758 PECOS PAC ID: 0446670764 Enrollment ID: I20201026001237 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Jeni Wolfe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285303099 PECOS PAC ID: 0941698161 Enrollment ID: I20211020002921 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Erin Brooke Hlad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396079661 PECOS PAC ID: 5294126595 Enrollment ID: I20211228001330 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Sharilyn Twidwell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1972111649 PECOS PAC ID: 2466848163 Enrollment ID: I20220406000326 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Ola Anyanwu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083360945 PECOS PAC ID: 0042697021 Enrollment ID: I20220512001177 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Sarah B Valerio |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831561919 PECOS PAC ID: 2365726536 Enrollment ID: I20220513000304 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Brooke Fandrich |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033785860 PECOS PAC ID: 0840666392 Enrollment ID: I20221025000696 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Olaoluwatomi Ogundimu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447994728 PECOS PAC ID: 0244582971 Enrollment ID: I20221118002586 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Sheridan Roling |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215539192 PECOS PAC ID: 8022488154 Enrollment ID: I20230105001183 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Esther Ubom Aruna |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477283075 PECOS PAC ID: 1153793005 Enrollment ID: I20230202002186 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Molly Barker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1366163800 PECOS PAC ID: 9032573068 Enrollment ID: I20230911000081 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Chinasa Oriaku |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588303788 PECOS PAC ID: 8325417058 Enrollment ID: I20230919000616 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Raven Long |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1053854703 PECOS PAC ID: 9133562705 Enrollment ID: I20240211000057 |
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
News Archive
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
A new study in mice reveals that increased body weight and high blood sugar as a result of consuming a high-fat diet may cause anxiety and depressive symptoms and measurable changes in the brain.
Implantable cardioverter-defibrillator use is associated with reduced short- and long-term mortality in patients with heart failure, according to late-breaking research presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in Circulation.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
Mindfully Reconnect Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1001 W 31st St, Cheyenne, WY 82001 Phone: 307-634-6883 Fax: 307-634-9462 | |
Rescare Wyoming, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6215 Clear Creek Pkwy, Cheyenne, WY 82007 Phone: 307-432-9824 | |
Kw Therapy, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1910 Pioneer Ave, Cheyenne, WY 82001 Phone: 970-315-2375 Fax: 844-965-9818 | |
2.0 Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2321 Dunn Ave, Cheyenne, WY 82001 Phone: 307-316-2757 Fax: 307-316-8811 | |
Gloria D Rutt Psyd Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2305 Coulter Drive, Cheyenne, WY 82009 Phone: 307-286-4106 Fax: 307-632-6588 | |
Speak Life Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1816 E 17th St, Cheyenne, WY 82001 Phone: 307-426-4204 | |
Cheyenne Child And Family Counseling Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 721 E Lincolnway, Cheyenne, WY 82001 Phone: 307-631-9213 |